DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $155,559 | +5.3% | 627 | +2.0% | 0.01% | +7.7% |
| Q2 2023 | $147,722 | -4.8% | 615 | 0.0% | 0.01% | -7.1% |
| Q1 2023 | $155,127 | -7.3% | 615 | -2.4% | 0.01% | -17.6% |
| Q4 2022 | $167,327 | +2.7% | 630 | 0.0% | 0.02% | -5.6% |
| Q3 2022 | $163,000 | -10.4% | 630 | -12.1% | 0.02% | -5.3% |
| Q2 2022 | $182,000 | -16.5% | 717 | -3.4% | 0.02% | -5.0% |
| Q1 2022 | $218,000 | +5.8% | 742 | +9.8% | 0.02% | -4.8% |
| Q3 2021 | $206,000 | +42.1% | 676 | +25.4% | 0.02% | +40.0% |
| Q2 2021 | $145,000 | +19.8% | 539 | 0.0% | 0.02% | +7.1% |
| Q1 2021 | $121,000 | +23.5% | 539 | +22.8% | 0.01% | +16.7% |
| Q4 2020 | $98,000 | +24.1% | 439 | +19.0% | 0.01% | +20.0% |
| Q3 2020 | $79,000 | +21.5% | 369 | 0.0% | 0.01% | +11.1% |
| Q2 2020 | $65,000 | +27.5% | 369 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $51,000 | -10.5% | 369 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $57,000 | +7.5% | 369 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $53,000 | 0.0% | 369 | 0.0% | 0.01% | 0.0% |
| Q2 2019 | $53,000 | +8.2% | 369 | 0.0% | 0.01% | +12.5% |
| Q1 2019 | $49,000 | +28.9% | 369 | 0.0% | 0.01% | +14.3% |
| Q4 2018 | $38,000 | -5.0% | 369 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $40,000 | +11.1% | 369 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $36,000 | 0.0% | 369 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $36,000 | +28.6% | 369 | +23.0% | 0.01% | +40.0% |
| Q4 2017 | $28,000 | +7.7% | 300 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $26,000 | +4.0% | 300 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $25,000 | -3.8% | 300 | 0.0% | 0.01% | 0.0% |
| Q1 2017 | $26,000 | +13.0% | 300 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $23,000 | -14.8% | 300 | -12.8% | 0.01% | -16.7% |
| Q3 2016 | $27,000 | -22.9% | 344 | 0.0% | 0.01% | -33.3% |
| Q2 2016 | $35,000 | +25.0% | 344 | +14.7% | 0.01% | +28.6% |
| Q1 2016 | $28,000 | 0.0% | 300 | 0.0% | 0.01% | -12.5% |
| Q4 2015 | $28,000 | +7.7% | 300 | 0.0% | 0.01% | +14.3% |
| Q3 2015 | $26,000 | 0.0% | 300 | 0.0% | 0.01% | 0.0% |
| Q2 2015 | $26,000 | -23.5% | 300 | -24.2% | 0.01% | -12.5% |
| Q1 2015 | $34,000 | 0.0% | 396 | 0.0% | 0.01% | -11.1% |
| Q4 2014 | $34,000 | +13.3% | 396 | 0.0% | 0.01% | 0.0% |
| Q3 2014 | $30,000 | +30.4% | 396 | +32.0% | 0.01% | +28.6% |
| Q2 2014 | $23,000 | 0.0% | 300 | 0.0% | 0.01% | -12.5% |
| Q1 2014 | $23,000 | 0.0% | 300 | 0.0% | 0.01% | 0.0% |
| Q4 2013 | $23,000 | 0.0% | 300 | 0.0% | 0.01% | -38.5% |
| Q3 2013 | $23,000 | +228.6% | 300 | +229.7% | 0.01% | +225.0% |
| Q1 2012 | $7,000 | 0.0% | 91 | 0.0% | 0.00% | -20.0% |
| Q4 2011 | $7,000 | – | 91 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |